Shares of WeightWatchers and Hims & Hers Health saw significant increases, with their stock prices rising by 5.4% and 10.2% respectively. This boost follows a recent announcement from the U.S. Food and Drug Administration (FDA).
The FDA stated it will reconsider its previous decision to ban pharmaceutical compounders from selling homemade versions of Eli Lilly's popular weight loss and diabetes medication. In response to a lawsuit filed by an industry organization, the FDA will allow these manufacturers to continue supplying the drugs while evaluating whether there's a shortage of tirzepatide.
